App aims to supercharge GLP-1 weight-loss drugs with personalized meal plans

NCT ID NCT07728669

First seen Jul 27, 2026 · Last updated Aug 12, 2026 · Updated 4 times

Summary

This trial tests whether a mobile app called NutriSteppe can improve blood sugar control and weight loss in adults with type 2 diabetes or obesity who are already taking GLP-1 medications like semaglutide. Over 12 weeks, half the participants will use the app for personalized meal planning, food tracking, and education, while the other half receives standard care. The main question is whether the app leads to better HbA1c levels and other health measures.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a mobile application called NutriSteppe that provides personalized meal planning, food diary, and dietary education
What this could lead to
If it works, this could point toward a simple, scalable way to boost the benefits of GLP-1 drugs through better diet tracking and support.
What could go wrong
This is a small, early-stage trial with 120 participants. The app's effect may be modest or hard to separate from the medication itself, and long-term adherence is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METABOLIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Kazakh Academy of Nutrition LLP

    RECRUITING

    Almaty, 050008, Kazakhstan

More trials for these conditions

Other studies related to the condition(s) this trial covers.